$250 | Single User
$500 | Site License
$750 | Global License

The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile
[Lowest Price Guaranteed: $250]

Published by Global Data: 27 Sep 2018 | 223631 | In Stock
Related Topics: Business , Equity , Financial , Healthcare , Infectious Disease , Pharmaceuticals

Introduction

Summary

The National Institute of Allergy and Infectious Diseases (NIAID), a subsidiary of National Institutes of Health is a research institute that provides technological and therapeutic solutions. The institute develops therapies, diagnostic tests, vaccines, and other technologies to understand, immunologic, treat and prevent infectious, and allergic diseases. It offers services such as grants and funding, research and training, and health information. NIAID supports basic and clinical research to understand the causes and mechanisms that lead to the development of allergic and immunologic diseases. The institute's research areas include infectious diseases such as tuberculosis and influenza, HIV/AIDS, biodefense; and immune-mediated diseases including asthma and allergy. NIAID is headquartered in Bethesda, Maryland, the US.

The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.

- Business Description - A brief description of the company's operations.

- Key Employees - A list of the key executives of the company.

- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors - A list of the key competitors of the company.

- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents
for The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Table of Contents

    Table of Contents 3

    List of Tables 6

    List of Figures 6

    The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

    The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

    The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

    The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

    The National Institute of Allergy and Infectious Diseases, Medical Devices Deals, 2012 to YTD 2018 11

    The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

    The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deal Details 15

    Partnerships 15

    BiondVax Pharma Enters into Agreement with National Institute of Allergy and Infectious Diseases 15

    Inspyr Therapeutics Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 16

    Geom Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 17

    Zavante Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Disease 18

    Maxcyte Enters into R&D Agreement with National Institute of Allergy and Infectious Diseases 19

    DesignMedix Enters into Agreement with The National Institute of Allergy and Infectious Diseases 20

    Chrysalis BioTherapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 21

    Evolva Enters into Agreement with National Institute of Allergy and Infectious Diseases 22

    RedHill Biopharma Enters into Agreement with NIAID 23

    GlaxoSmithKline Enters into Research Agreement with NIAID 24

    PepTcell Enters into Research and Development Agreement National Institute of Allergy and Infectious Diseases 25

    SRI International Enters into Agreement with National Institute of Allergy and Infectious Diseases 26

    Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 27

    GenVec Enters into Research Agreement with LMIV 28

    GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 29

    BioAegis Therapeutics Enters into Research Agreement with the National Institute of Allergy and Infectious Disease 30

    Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 31

    PharmAthene Enters into Agreement with National Institutes of Allergy and Infectious Diseases 33

    Knopp Biosciences Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 34

    Soligenix Enters into Contract with National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority 35

    DFH Pharma Enters Into Co-Development Agreement With NIAID For HIV Maturation Inhibitor Drugs 36

    ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 37

    Licensing Agreements 38

    Butantan Institute Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 38

    Exxell BIO Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 39

    Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 40

    The National Institute of Allergy and Infectious Diseases - Key Competitors 41

    The National Institute of Allergy and Infectious Diseases - Key Employees 42

    The National Institute of Allergy and Infectious Diseases - Locations And Subsidiaries 43

    Head Office 43

    Other Locations & Subsidiaries 43

    Recent Developments 44

    Government and Public Interest 44

    Sep 12, 2018: TechnoVax awarded .5 million NIH grant to further develop a universal VLP-based influenza vaccine 44

    Aug 28, 2018: UTEP Scientists Awarded M to Improve Treatment for Chagas Disease 45

    Aug 02, 2018: UMD-Led team receives .7 Million NIH grant for first-of-its-kind tick-borne disease research 46

    Jul 25, 2018: HIV remission free of antiretroviral therapy is a feasible goal 47

    Jul 11, 2018: NIAID scientists create 3D structure of 1918 influenza virus-like particles 48

    Jun 29, 2018: Same Vaccine Concept for Ebola Appears Effective Against Nipah Virus 49

    Jun 21, 2018: VTCRI scientist awarded million grant from the National Institutes of Health to study the body’s immune memory response 50

    May 30, 2018: NIH scientists show how tularemia bacteria trick cells to cause disease 52

    May 16, 2018: Lab-confirmed prenatal exposure to Zika is linked to cardiac defects in infants 53

    Apr 25, 2018: Anti-HIV drug combination does not increase preterm birth risk, study suggests 54

    Apr 16, 2018: Epstein-Barr virus protein can “switch on” risk genes for autoimmune diseases 55

    Mar 27, 2018: NIAID Scientists Discover Rare Genetic Cause of Crohn’s Disease 56

    Mar 22, 2018: NIH scientists say advanced vaccines could limit future outbreaks 57

    Mar 21, 2018: Islet transplantation improves quality of life for people with hard-to-control type 1 diabetes 58

    Mar 19, 2018: Newly described human antibody prevents malaria in mice 60

    Mar 09, 2018: NIH experts call for transformative research approach to end tuberculosis 61

    Mar 08, 2018: NIAID scientists assess transmission risk of familial human prion diseases to mice 62

    Mar 08, 2018: Monoclonal antibodies crucial to fighting emerging infectious diseases, say NIH officials 63

    Mar 05, 2018: Broadly neutralizing antibody treatment may target viral reservoir in monkeys 64

    Feb 28, 2018: NIAID unveils strategic plan for developing a universal influenza vaccine 65

    Feb 12, 2018: Inovio and The Wistar Institute Receive More Than .6 Million in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria 66

    Feb 05, 2018: New Research Suggests Your Immune System Can Protect Against MRSA Infections 67

    Jan 24, 2018: NIH begins large HIV treatment study in pregnant women 69

    Jan 03, 2018: Stem cell transplant for severe scleroderma improves survival, quality of life 71

    Dec 05, 2017: Scientists Find Potential Weapons for the Battle Against Antibiotic Resistance 73

    Dec 04, 2017: Fighting HIV through a better delivery method of anti-retrovirals 75

    Nov 30, 2017: New treatment investigated for brain tapeworm infection 76

    Oct 24, 2017: Identifying the mechanism for a new class of antiviral drugs could hasten their approval 77

    Oct 17, 2017: Pair of Discoveries Illuminate New Paths to Flu and Anthrax Treatments 78

    Sep 28, 2017: Neuro-Immune Crosstalk in Allergic Asthma 80

    Sep 27, 2017: NIH announces centers for myalgic encephalomyelitis/chronic fatigue syndrome research 82

    Sep 20, 2017: Texas Biomed Scientists part of .5 million NIH project aimed at combating drug resistance in the malaria parasite 84

    Sep 05, 2017: Zika virus selectively infects and kills glioblastoma cells in mice 85

    Aug 22, 2017: CURE Pharmaceutical Subsidiary, Oak Therapeutics, Completes Critical Milestone in Phase 1 of NIH Grant to Develop Oral Dissolvable Strip for Tuberculosis 86

    Aug 21, 2017: Texas Biomed part of team receiving five-year, .4 million NIH grant for novel TB vaccine testing 87

    Jul 31, 2017: Biomedical Researcher Gets .9 Million to Study Influenza Vaccines and Cross-Protective Immunity Biomedical Researcher Gets .9 Million to Study Influenza Vaccines and Cross-Protective Immunity 89

    Jul 18, 2017: OMRF researcher tests new approach for treating deadly blood infection 90

    Jul 13, 2017: Experimental Zika Virus Vaccines Restrict In Utero Virus Transmission in Mice 91

    Jun 19, 2017: .6 Million NIH Grant Awarded to NYBC Scientist for Research on River Blindness Vaccine 92

    May 01, 2017: NIH Research Improves Health for People with Asthma 93

    Apr 21, 2017: Researchers receive million grant for research on drug-resistant malaria 95

    Feb 01, 2017: Stem cell transplants may induce long-term remission of multiple sclerosis 96

    Jan 17, 2017: NIAID Awards Paragon Bioservices a Multiple Award IDIQ Contract valued up to 9M for Preclinical Drug Development Services 97

    Product News 98

    Oct 03, 2017: Oak Therapeutics Announces Results of Bioequivalence Study of Company’s Oral Dissolvable Strip for Tuberculosis 98

    Jun 12, 2018: GenScript Supports the Development of a Novel HIV Vaccine 99

    May 07, 2018: NIH clinical trial to track outcomes of kidney transplantation from HIV-positive donors to HIV-positive recipients 100

    May 03, 2018: Bacteria therapy for eczema shows promise in NIH study 102

    Mar 13, 2018: NIH scientists describe potential antibody approach for treating multidrug-resistant Klebsiella pneumoniae 104

    Other Significant Developments 105

    Apr 09, 2018: NIH Scientists Develop Macaque Model to Study Crimean-Congo Hemorrhagic Fever 105

    Feb 21, 2018: NIH program to accelerate therapies for arthritis, lupus releases first datasets 106

    Jan 24, 2017: NIH Advances Understanding of Defenses Against Antibiotic-Resistant Klebsiella Bacteria 107

    Appendix 108

    Methodology 108

    About GlobalData 108

    Contact Us 108

    Disclaimer 108

List Of Tables
in The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile

List of Tables

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Key Facts 2

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

The National Institute of Allergy and Infectious Diseases, Deals By Therapy Area, 2012 to YTD 2018 10

The National Institute of Allergy and Infectious Diseases, Medical Devices Deals, 2012 to YTD 2018 11

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

BiondVax Pharma Enters into Agreement with National Institute of Allergy and Infectious Diseases 15

Inspyr Therapeutics Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 16

Geom Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 17

Zavante Therapeutics Enters into Agreement with National Institute of Allergy and Infectious Disease 18

Maxcyte Enters into R&D Agreement with National Institute of Allergy and Infectious Diseases 19

DesignMedix Enters into Agreement with The National Institute of Allergy and Infectious Diseases 20

Chrysalis BioTherapeutics Enters into Agreement with National Institute of Allergy and Infectious Diseases 21

Evolva Enters into Agreement with National Institute of Allergy and Infectious Diseases 22

RedHill Biopharma Enters into Agreement with NIAID 23

GlaxoSmithKline Enters into Research Agreement with NIAID 24

PepTcell Enters into Research and Development Agreement National Institute of Allergy and Infectious Diseases 25

SRI International Enters into Agreement with National Institute of Allergy and Infectious Diseases 26

Zydus Cadila Healthcare Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 27

GenVec Enters into Research Agreement with LMIV 28

GeoVax Labs Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 29

BioAegis Therapeutics Enters into Research Agreement with the National Institute of Allergy and Infectious Disease 30

Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 31

PharmAthene Enters into Agreement with National Institutes of Allergy and Infectious Diseases 33

Knopp Biosciences Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 34

Soligenix Enters into Contract with National Institute of Allergy and Infectious Diseases and Biomedical Advanced Research and Development Authority 35

DFH Pharma Enters Into Co-Development Agreement With NIAID For HIV Maturation Inhibitor Drugs 36

ImmunoVaccine Enters into Research Agreement with National Institute of Allergy and Infectious Diseases 37

Butantan Institute Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 38

Exxell BIO Enters into Licensing Agreement with National Institute of Allergy and Infectious Diseases 39

Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 40

The National Institute of Allergy and Infectious Diseases, Key Competitors 41

The National Institute of Allergy and Infectious Diseases, Key Employees 42

The National Institute of Allergy and Infectious Diseases, Subsidiaries 43

List Of Figures, Charts and Diagrams
in The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile

List of Figures

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

The National Institute of Allergy and Infectious Diseases, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

The National Institute of Allergy and Infectious Diseases, Medical Devices Deals, 2012 to YTD 2018 11

Additional Details

Publisher

Global Data

Publisher Information

Reference

223631 | GDPH142862D

Number of Pages

108

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Lawrence Livermore National Laboratory - Medical Equipment - Deals and Alliances Profile
SummaryLawrence Livermore National Laboratory (LLNL) is a national security technology provider. The...
25 Feb 2016 by Global Data USD $250 More Info
National University of Singapore - Medical Equipment - Deals and Alliances Profile
SummaryNational University of Singapore (NUS) is an educational institution that provides education ...
25 Feb 2016 by Global Data USD $250 More Info
Centre National de la Recherche Scientifique - Medical Equipment - Deals and Alliances Profile
SummaryCentre National de la Recherche Scientifique (CNRS) is an educational center that offers rese...
24 Feb 2016 by Global Data USD $250 More Info
National HealthCare Corporation (NHC) - Financial and Strategic SWOT Analysis Review
SummaryNational HealthCare Corporation (NHC) is a health care service provider that offers home-care...
09 Jan 2016 by Global Data USD $300 More Info
National Research Corporation (NRCIB) - Financial and Strategic SWOT Analysis Review
SummaryNational Research Corporation (NRC) is a healthcare organization that provides patient-center...
09 Jan 2016 by Global Data USD $300 More Info
National HealthCare Corporation (NHC) - Financial and Strategic SWOT Analysis Review
SummaryNational HealthCare Corporation (NHC) is a health care service provider that offers home-care...
08 Nov 2015 by Global Data USD $300 More Info
National Research Corporation (NRCIB) - Financial and Strategic SWOT Analysis Review
SummaryNational Research Corporation (NRC) is a healthcare organization that provides patient-center...
08 Nov 2015 by Global Data USD $300 More Info
Lawrence Livermore National Laboratory - Medical Equipment - Deals and Alliances Profile
SummaryLawrence Livermore National Laboratory (LLNL) is a national security technology provider. The...
23 Oct 2015 by Global Data USD $250 More Info
National Cancer Institute - Medical Equipment - Deals and Alliances Profile
SummaryNational Cancer Institute (NCI), a subsidiary of National Institutes of Health is a cancer re...
23 Oct 2015 by Global Data USD $250 More Info
Institut National de la Sante et de la Recherche Medicale - Medical Equipment - Deals and Alliances Profile
SummaryInstitut National de la Sante et de la Recherche Medicale (Inserm) is a medical research inst...
16 Oct 2015 by Global Data USD $250 More Info

This report is published by Global Data

Download Free Report Summary PDF

The National Institute of Allergy and Infectious Diseases - Pharmaceuticals & Healthcare - Deals and Alliances Profile | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...